Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

SRR8518401

— · F

df020413-38a1-52c1-8084-5fbc6980c01c

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
F
subtype
F

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • OXIDATIVE_PHOSPHORYLATION+0.490
  • PROTEIN_SECRETION+0.440
  • CHOLESTEROL_HOMEOSTASIS+0.420
  • MTORC1_SIGNALING+0.420
  • FATTY_ACID_METABOLISM+0.400
  • ANDROGEN_RESPONSE+0.370
  • ADIPOGENESIS+0.350
  • BILE_ACID_METABOLISM+0.350
  • PEROXISOME+0.320
  • XENOBIOTIC_METABOLISM+0.320

Top 10 suppressed

  • WNT_BETA_CATENIN_SIGNALING-0.520
  • INTERFERON_ALPHA_RESPONSE-0.410
  • MYC_TARGETS_V2-0.350
  • MYOGENESIS-0.330
  • G2M_CHECKPOINT-0.310
  • E2F_TARGETS-0.290
  • MITOTIC_SPINDLE-0.270
  • INTERFERON_GAMMA_RESPONSE-0.260
  • NOTCH_SIGNALING-0.240
  • APICAL_SURFACE-0.200

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR8518149
breast-umap@18
—F0.877
2SRR4195681
colon-landscapes@1
——0.829
3SRR8518177
breast-umap@18
—F0.812
4TCGA-E2-A1LB-01A-11R-A144-07
breast-umap@18
—F0.798
5SRR29022837
breast-umap@18
—F0.785
6SRR8518315
breast-umap@18
—F0.777
7TCGA-D8-A1JF-01A-11R-A13Q-07
breast-umap@18
—F0.773
8GSM6454747
breast-umap@18
—F0.767
9SRR8518325
breast-umap@18
—F0.765
10SRR8518413
breast-umap@18
—F0.753

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 28 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
OXIDATIVE_PHOSPHORYLATION0.490Remibrutinib— uncovered
PROTEIN_SECRETION0.440Remibrutinib— uncovered
CHOLESTEROL_HOMEOSTASIS0.420Remibrutinib— uncovered
MTORC1_SIGNALING0.420Inavolisib— uncovered
FATTY_ACID_METABOLISM0.400Inavolisib— uncovered
ANDROGEN_RESPONSE0.370Inavolisib— uncovered
ADIPOGENESIS0.350Inavolisib— uncovered
BILE_ACID_METABOLISM0.350Inavolisib— uncovered
PEROXISOME0.320Idelalisib— uncovered
XENOBIOTIC_METABOLISM0.320Inavolisib— uncovered
GLYCOLYSIS0.290Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.280Inavolisib— uncovered
COAGULATION0.190Binimetinib— uncovered
PI3K_AKT_MTOR_SIGNALING0.180Inavolisib— uncovered
KRAS_SIGNALING_UP0.150Inavolisib— uncovered
HEME_METABOLISM0.130Temsirolimus— uncovered
PANCREAS_BETA_CELLS0.130Cobimetinib— uncovered
APOPTOSIS0.120Idelalisib— uncovered
COMPLEMENT0.120Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.120Inavolisib— uncovered